Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Germany

Marie Skłodowska-Curie Action · Running

ProAPP PROTAC-driven Protein degradation by Proteasome during Antigen Processing and Presentation (ProAPP)

Coordinator
Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften eV, Germany
Runs
1 August 2022 to 31 October 2024
Status
Running
EU funding
€190k
Total cost
—
Partners
1 organisations in 1 countries
Type
Marie Skłodowska-Curie Action
Grant agreement
101065466

What the project is doing

In the project's own words, from its summary on CORDIS.

PROteolysis TArgeting Chimera (PROTAC) is a new and attractive therapeutic approach that regulates a target protein by channeling it to the proteasome for degradation (an energy-demanding pathway). Concurrently, proteasomes also play a central role in generating the peptide repertoire for antigen presentation on the Human Leukocyte Antigen-I (HLA-I) molecules. A few years after PROTAC was invented, proteasomes were found to catalyze not only canonical peptide bond hydrolysis, but are also capable of “cut-and-paste” events, i.e. generating spliced peptides, which have been shown to be frequently presented n HLA-I immunopeptidomes.

It is unclear how PROTAC-driven proteasome degradation modulates the spliced and non-spliced peptide repertoire derived from a targeted protein. Alterations in peptide variety and quantity produced by proteasome may lead to strong implications on the HLA-I immunopeptidome, and, hence, could result in immune implications. Therefore, using the key oncoprotein KRAS as a PROTAC’s target, this study intends to understand: (i) how PROTAC-driven KRAS degradation affects cellular pathways on a system-wide level; (ii) the impact of PROTAC on KRAS derived peptide repertoire generated by proteasomes; (iii) to what extent PROTAC enhances KRAS derived peptide presentation on HLA-I molecules.

Through the combination of a multidisciplinary approach; molecular biology, biochemistry, proteomics, bioinformatics and cellular immunology, this study will provide a better fundamental understanding of the effect of PROTAC-KRAS on the cellular proteome, proteasome-derived peptide repertoire (spliced and non-spliced peptides) and HLA-I immunopeptidome landscape, thus, provide insights into the suitability of PROTAC-KRAS application as a therapeutic approach for anti-cancer therapies.

Additionally, this project will deepen our understanding of the role of spliced peptides in the antigen processing and presentation pathway.

Topics

Who is involved

OrganisationCityCountryRole
Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften eVMunchenGermanyCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI